Newer advances in the Management of Atopic Dermatitis & the role of PDE4 inhibitor

Speciality: Dermatology

Description:

 A warm welcome to all the medical professionals in this interesting session on Newer advances in the Management of Atopic Dermatitis & the role of PDE4 inhibitor
Recent advances in the management of atopic dermatitis (AD) have revolutionized treatment options, particularly for patients with moderate to severe disease. Traditional therapies, like topical corticosteroids and emollients, often provide limited relief in severe cases. Newer treatments, such as biologics (e.g., dupilumab) and small molecule inhibitors, have emerged, targeting the underlying immune pathways involved in AD. These innovations focus on reducing inflammation, improving skin barrier function, and controlling symptoms more effectively over the long term.
Phosphodiesterase 4 (PDE4) inhibitors, such as crisaborole, represent a significant advancement in treating AD. By inhibiting the PDE4 enzyme, these drugs reduce the production of inflammatory cytokines, thus alleviating symptoms like itching and redness. PDE4 inhibitors are particularly beneficial for patients who require steroid-sparing options or for those who have milder forms of AD that need long-term management. Their targeted mechanism offers a safer profile with fewer side effects, making them an attractive option in the evolving landscape of AD therapy.
Therefore, get an overall knowledge of newer advances in the management of atopic dermatitis & the role of PDE4 inhibitors. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.

See More Webinars @ Hidoc Webinars